EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell features

Claudia De Pasquale, Fabiana Drommi, Alessia Calabrò, Cirino Botta, Giacomo Sidoti Migliore, Paolo Carrega, Grazia Vento, Amirhossein Gaeini, Gaetana Pezzino, José Freni, Irene Bonaccorsi, Massimo Vitale und 7 weitere

Journal of Allergy and Clinical Immunology · 2025-06 · 155 (6) · 1981-1992

DOI: 10.1016/j.jaci.2025.01.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-06. Verfasst von Claudia De Pasquale und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Killer Cells, Natural, CD8-Positive T-Lymphocytes, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The Pfizer-BioNtech vaccine, also known as BNT162b2, was developed using a novel technology based on mRNA and protects against coronavirus disease 2019 (COVID-19) via induction of specific antibody and T-cell responses. Much less is known about the broader effects of this new class of vaccines on unconventional cellular components of the immune system. OBJECTIVES: We aimed to characterize a subset of unconventional T cells emerging following BNT162b2 mRNA vaccination. METHODS: Peripheral blood from a total of 30 human healthy individuals who received 2 doses of the BNT162b2 mRNA vaccine was collected for the analysis of T-cell compartment by using multiparametric flow cytometry and single-cell transcriptome analyses. RESULTS: In the peripheral blood of individuals undergoing BNT162b2 vaccination, we observed a sizable fraction of CD8+ T cells expressing CD16, a low-affinity FcR for IgG. These cells were severe acute respiratory coronavirus 2-specific, characterized by IFN-γ response gene transcripts and stimulation through CD16 and other natural killer (NK)-cell innate receptors elicited a functional response. Both CD16 and NKp30 could be induced on NKp80+ CD8+ T cells and the engagement of NKp80 in combination with CD16 resulted in synergic effects. CD16+ CD8+ T cells also showed a high expression of the inhibitory receptor G protein-coupled receptor 56 (GPR56), capable of limiting their activation via CD16. CONCLUSIONS: These data indicate that BNT162b2 COVID-19 vaccination provides an additional large fraction of antibody-dependent cellular cytotoxicity (ADCC)-capable effector cells, endowed with innate functions and therefore able to potentially counteract a much wider array of diseases, including cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalCD8-Positive T-LymphocytesCOVID-19SARS-CoV-2Receptors, IgGCOVID-19 VaccinesHumansBNT162 VaccineAdultFemaleMaleVaccinationMiddle AgedGPI-Linked Proteins

Stichwörter der Autor:innen

ADCCBNT162b2 mRNA vaccineCD16/FcγRIIIANK cellshumaninnate-like T cellsspike-specific CD8(+) T cells

Substanzen

BNT162 VaccineReceptors, IgGCOVID-19 VaccinesFCGR3B protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Laboratory of Immunology and Biotherapy, Department Human Pathology "G. Barresi", University of Messina, Messina, Italy.
  • Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy.
  • Translational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Department of Experimental Medicine, University of Genoa, Genova, Italy.
  • Unit of Experimental Pathology and Immunology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy.
  • Biotherapy Unit, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine, University of Genoa, Genova, Italy.

Förderung

  • Intramural NIH HHS
  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro
  • Ministero dell’Istruzione, dell’Università e della Ricerca
  • Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca
  • Division of Intramural Research
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

De Pasquale, C., Drommi, F., Calabrò, A., Botta, C., Sidoti Migliore, G., Carrega, P., Vento, G., Gaeini, A., Pezzino, G., Freni, J., Bonaccorsi, I., Vitale, M., Filaci, G., Fenoglio, D., Iemmo, R., Costa, G., Cavaliere, R., Ferlazzo, G., & Campana, S. (2025). BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell features. Journal of Allergy and Clinical Immunology, 155(6), 1981-1992. https://doi.org/10.1016/j.jaci.2025.01.024

Vancouver

De Pasquale C, Drommi F, Calabrò A, Botta C, Sidoti Migliore G, Carrega P, et al. BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell features. Journal of Allergy and Clinical Immunology. 2025;155(6):1981-1992. doi:10.1016/j.jaci.2025.01.024

BibTeX
@article{DePasquale2025,
  author = {De Pasquale, Claudia and Drommi, Fabiana and Calabrò, Alessia and Botta, Cirino and Sidoti Migliore, Giacomo and Carrega, Paolo and Vento, Grazia and Gaeini, Amirhossein and Pezzino, Gaetana and Freni, José and Bonaccorsi, Irene and Vitale, Massimo and Filaci, Gilberto and Fenoglio, Daniela and Iemmo, Raffaella and Costa, Gregorio and Cavaliere, Riccardo and Ferlazzo, Guido and Campana, Stefania},
  title = {BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with natural killer cell features},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2025},
  volume = {155},
  number = {6},
  pages = {1981--1992},
  doi = {10.1016/j.jaci.2025.01.024}
}
Kostenlos starten →